A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.
We have tested a new type of immunoliposomes which may effectively mediate the targeting of enzymes to be used for site-specific prodrug activation (immuno-enzymosomes). The enzyme beta-glucuronidase, capable of activating the prodrug epirubicin-glucuronide (epi-glu), was coupled to the external surface of immunoliposomes directed towards ovarian cancer cells. A significant increase in cytotoxicity of the prodrug epi-glu was shown when the in vitro cultured cancer cells were pretreated with these immuno-enzymosomes.
Vingerhoeds
M H
MH
Department of Pharmaceutics, Faculty of Pharmacy, Utrecht University, The Netherlands.
Haisma
H J
HJ
van Muijen
M
M
van de Rijt
R B
RB
Crommelin
D J
DJ
Storm
G
G
D000911:Antibodies, Monoclonal; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004337:Drug Carriers; D015251:Epirubicin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity*; D005260:Female; D005965:Glucuronates / Q000378:metabolism* / Q000633:toxicity; D005966:Glucuronidase / Q000378:metabolism*; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D008081:Liposomes; D010051:Ovarian Neoplasms; D011355:Prodrugs / Q000378:metabolism* / Q000633:toxicity; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D004337:Drug Carriers; D005965:Glucuronates; D007140:Immunoglobulin Fab Fragments; D008081:Liposomes; D011355:Prodrugs; C074868:epidoxorubicin glucuronide; D015251:Epirubicin; D005966:Glucuronidase